top of page

We are a Neuroimmunology Research Laboratory based in Toronto, affiliated with St. Michael's Hospital, the Keenan Research Centre for Biomedical Science, and the University of Toronto. We investigate novel concepts that underlie the complexities of multiple sclerosis (MS).


Primary Areas of Interest

Over the last years, the treatment options for multiple sclerosis (MS) have expanded dramatically. Optimizing therapeutic approaches for people with MS requires personalized medicine. We believe that a more comprehensive understanding of the pathology underlying multiple sclerosis will be necessary to develop new disease-biomarkers and therapies, ultimately improving clinical outcomes for people with MS.



Multiple sclerosis is an inflammatory disease of the central nervous system; its etiology and pathophysiology remain incompletely understood. Several lines of evidence support that aberrant activation of the immune system plays a central role in multiple sclerosis.


Multiple sclerosis is also a demyelinating and neurodegenerative disorder of the central nervous system. People with multiple sclerosis experience acute neurological symptoms when inflammatory lesions appear in critical areas of the brain or spinal cord. Cumulative neuronal loss is the primary determinant of long-term prognosis in multiple sclerosis.


Recent studies have highlighted the value of blood and cerebrospinal fluid biomarkers in multiple sclerosis. Such biomarkers help better understand an individual’s diagnosis and prognosis with the ultimate goal of choosing the most appropriate treatment.


Schneider Lab

Keenan Research Centre for Biomedical Science
St. Michael's Hospital
209 Victoria Street
Toronto, Ontario, Canada, M5B 1W8

Thanks for submitting!

bottom of page